LivaNova 3Q 2026: Revenue $393.15M, Net income $34.29M, EPS $0.11— 10-Q Summary
LivaNova reported Q3 2026 revenue of $393.15M, up 9.9% YoY, with net income rising 28% to $34.29M. EPS was $0.11, down 77.6% YoY. Cardiopulmonary and Neuromodulation revenues grew 10.9% and 11.1%, respectively. The FDA approved the aura6000 System in March 2026. Supply constraints persist but have not materially affected operations.
How this was made
The 30-second read
Why it matters
The Q3 2026 results provide the first public data on the company's recent product launches and FDA approvals, informing valuation models.
Market read
Earnings release is the primary catalyst for LIVN's near‑term price action and may influence med‑tech sector sentiment.
What to watch
Supply‑chain constraints remain, and the new FDA approval for the aura6000 System could drive future upside.
Background
LivaNova PLC (LIVN) is a global medical technology company focused on cardiac surgery and neuromodulation.
Ticker impact
LivaNova posted its Q3 2026 earnings with revenue up 9.9% YoY and EPS falling to $0.11, a fresh SEC 10‑Q filing.
likely slight pressure as investors digest lower EPS despite revenue beat
Revenue beat suggests operational strength, but EPS drop signals margin compression; market may react cautiously.
Market effects
Positive revenue growth may lift the broader medical device sector, but margin concerns could temper enthusiasm.
European and U.S. markets may see modest adjustments in med‑tech indices.
Limited to investors tracking med‑tech earnings; no broad macro impact.
Counterpoint
The EPS decline could be a buying opportunity if the market overreacts to margin compression.
Key entities
- CompanyLivaNova PLC
Medical device manufacturer reporting Q3 2026 earnings.
- RegulatorFDA
Granted pre‑market approval for the aura6000 System.
